The Food and Drug Administration approved a second drug Friday to battle opioid overdoses.

Drug manufacturer Harm Reduction Therapeutics produced RiVive to reverse overdoses. It will not require a prescription and will be available for purchase over the counter by next year.

INFLATION DECLINED TO 3% IN JUNE, ACCORDING TO KEY GAUGE WATCHED BY FED

Harm Reduction Therapeutics is the first nonprofit pharmaceutical company to receive approval for its opioid reversal drug. It plans to make 200,000 doses for free.

"Ensuring naloxone is widely available, especially as an approved OTC product, makes a critical tool available to help protect public health," FDA Commissioner Robert Califf said in a statement. "The agency has long prioritized access to naloxone products, and we welcome manufacturers of other naloxone products to discuss potential nonprescription development programs with the FDA."

Last year, the United States saw over 100,000 overdose deaths. In March 2023, The FDA approved the first over-the-counter naloxone nasal spray.

CLICK HERE TO READ MORE FROM THE WASHINGTON EXAMINER

Men experience overdose deaths at a two to three times greater rate than women across all age brackets, states, and types of drugs, per a study published in June and conducted by the cooperation of scientists at the Icahn School of Medicine at Mt. Sinai in New York and the National Institute on Drug Abuse from the National Institutes of Health.

Overdose deaths across all demographic categories have increased fivefold since 2000, and the rate of overdoses has spiked since 2019.